# Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)

> **NCT05705167** · PHASE2 · TERMINATED · sponsor: **PharmaMar** · enrollment: 37 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Plitidepsin

## Key facts

- **NCT ID:** NCT05705167
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-19
- **Primary completion:** 2024-03-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Significant difficulties in the recruitment of participants.
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705167, "Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05705167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*